7 results about "Cucurbitacin B" patented technology

The present application relates to a composition for inhibiting melanin production, its application, and a whitening method. The composition comprises active ingredients and excipients, wherein the active ingredients include one or more combinations of cucurbitacin B, mulberry root C, and hypocrellin A. Experimental verification demonstrates that any monomer of cucurbitacin B, mulberry root C, or hypocrellin A, or any combination thereof, exhibits significant inhibition of mushroom tyrosinase activity, inhibits tyrosinase activity in B16F10 cells, and inhibits melanin production in B16F10 cells, with low cytotoxicity. Application of the composition in cosmetic or pharmaceutical formulations can effectively whiten and combat melasma.

The invention discloses application of cucurbitacin B in preparation of a medicine for treating or preventing bombyx mori nuclear polyhedrosis virus. The research shows that the terpenoid cucurbitacin B can effectively inhibit replication of the bombyx mori nuclear polyhedrosis virus (BmNPV) in bombyx mori cells and bombyx mori bodies; the cucurbitacin B can be used for inhibiting the replication of the virus in bombyx mori cells and bombyx mori bodies through proper concentration and drug adding time, a new thought is provided for prevention of bombyx mori BmNPV infection, and a foundation is laid for prevention and treatment of virus infection in sericulture production.

The present application relates to the technical field of biological medicine, and specifically discloses a small-molecule coupling compound targeting ASGPR, which has the following general formula: wherein X is a small-molecule ligand with the ability to target ASGPR; and Y is a derivative of cucurbitacin B. . The small-molecule coupling compound can be used in the preparation of a drug targeting ASGPR and having the functions of precise chemotherapy and radiotherapy sensitization. The small-molecule coupling compound prepared by the present application can achieve precise killing of liver cancer cells; the water solubility of cucurbitacin B is improved after coupling; the small-molecule coupling compound integrates precise chemotherapy and radiotherapy sensitization, and can significantly enhance the cancer-killing effect in combination with low-dose radiotherapy; and the small-molecule coupling compound has no obvious systemic toxicity and is well tolerated by patients.

The invention discloses application of cucurbitacine B (abbreviated as CuB) in preparation of drugs for relieving pulmonary fibrosis progress, and particularly relates to application of CuB in regulation and control of M2 macrophage polarization by inhibiting PI3K / AKT signaling pathways, by exploring the mechanism, a new therapeutic approach can be found for pulmonary fibrosis PF, theoretical and experimental foundations are provided for pathogenesis of PF and novel drug research and development, and the application of the cucurbitacine B in regulation and control of M2 macrophage polarization by inhibiting PI3K / AKT signaling pathways is developed. The method can be extended to provide a modern experimental basis for traditional Chinese medicine treatment of PF, research on the disease formation mechanism of PF and CuB drug targets is expected to promote theoretical development of subjects, meet clinical practical requirements, fill the theoretical blank and further promote industry development in the field of PF research, and the method has great social and economic benefits and application and popularization prospects.

This invention discloses the application of cucurbitacin B in the preparation of drugs for the treatment or prevention of silkworm nucleopolyhedrovirus. The research of this invention shows that the terpene compound cucurbitacin B can effectively inhibit the replication of silkworm nucleopolyhedrovirus (BmNPV) in silkworm cells and within the silkworm. By using appropriate concentrations and drug addition times, cucurbitacin B can inhibit the replication of the virus in silkworm cells and within the silkworm, providing a new approach for the prevention of BmNPV infection in silkworms and laying the foundation for the prevention and control of viral infections in sericulture.

The application discloses a cucurbitacin B derivative A2, a preparation method and application thereof, and the structural formula of the cucurbitacin B derivative A2 is provided. 50 The cucurbitacin B derivative A2 provided by the application has a strong inhibitory effect on the proliferation activity of a human non-small cell lung cancer cell line A549, and the IC value is only 0.009 muM, which is increased by nearly 10 times than the inhibitory activity of cucurbitacin B on the proliferation of A549, and the toxicity to normal cells L02 is reduced by nearly 10 times, and the selectivity coefficient is increased by nearly 100 times than cucurbitacin. The xenograft mouse experiment result is consistent with the cell result, and can be used as a candidate drug for treating human non-small cell lung cancer; the preparation method has the advantages of rich raw material source, mild reaction condition, convenient operation in reaction process, cheap and easily obtained reagent, low toxicity or non-toxicity, low cost and suitability for industrial production.

The present invention belongs to the field of biopharmaceutical technology, and specifically relates to a method and application for preparing cucurbitacin B derivatives by strong acid dehydration and peroxyacid oxidation. The present invention utilizes strong acid to catalyze the dehydration of cucurbitacin B and peroxyacid to oxidize the carbon-carbon double bond of cucurbitacin B, provides a variety of structural modification methods for cucurbitacin B, and synthesizes a series of novel cucurbitacin B derivatives. Subsequently, by using human breast cancer MCF-7 cells and human kidney epithelial HEK-293 cells to verify its proliferation inhibition effect and specificity, it was found that the anti-tumor activity of the compound was retained, and the selectivity index was improved compared to cucurbitacin B, which is worthy of further study.